MetaCap

InflaRx N.V. (IFRX) vs Veraxa Biotech (VRXA)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

InflaRx N.V. (IFRX) has outperformed Veraxa Biotech (VRXA) over the past year, losing 11.9% versus a loss of 90.1%. InflaRx N.V. is the larger company by market cap ($153.3 million vs $147.1 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

IFRX-11.86%VRXA-90.10%
+147%+22%-102%
Nov 21, 20251 yearNov 20, 2026
IFRX-33.33%VRXA-89.58%
+110%+5%-100%
Sep 30, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

IFRX versus VRXA key metrics
MetricIFRXVRXA
Share price$1.04$1.04
Market cap$153.26M$147.06M
1-day change-4.59%+0.97%
YTD return+2.97%-90.25%
1-year return-11.86%-90.10%
5-year return-79.53%—
EPS (TTM)$-0.37$-0.57
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
52-week high$2.95$27.36
52-week low$0.798$0.90
Distance from 52-week high-64.73%-96.20%
Analyst consensusnone—
Avg. price target upside+696.15%—
Average volume868.66K267.82K
Shares outstanding147.37M141.41M
Employees65—
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • IFRX has outperformed VRXA by 78.2 percentage points over the past year.

About InflaRx N.V.

IFRX stock →

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator to treat variety of autoimmune and other inflammatory diseases.

Health Care · Biotechnology: Pharmaceutical Preparations · 65 employees

About Veraxa Biotech

VRXA stock →

Veraxa Biotech AG develops antibody-based therapeutics and antibody-drug conjugates for cancer treatment. The company develops antibody-based therapeutics, including antibody-drug conjugates and bispecific antibody formats, and offers a proprietary technology platform for functional antibody screening and bioconjugation.

Health Care · Biotechnology: Pharmaceutical Preparations

IFRX vs VRXA FAQ

Which is bigger, InflaRx N.V. or Veraxa Biotech?

InflaRx N.V. (IFRX) is larger, with a market capitalization of $153.26M compared with $147.06M for Veraxa Biotech (VRXA).

Which stock has performed better over the past year, IFRX or VRXA?

IFRX returned -11.86% over the past 12 months, compared with -90.10% for VRXA (price return, excluding dividends). Past performance does not predict future results.

Are InflaRx N.V. and Veraxa Biotech in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons